SLS — SELLAS Life Sciences Group Inc · catalysts, narrative & risks

Snapshot (as of 2026-10-13)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company developing novel cancer therapeutics, primarily galinpepimut-S (GPS), a WT1-targeting immunotherapy, and SLS009 (tambiciclib), a CDK9 inhibitor [25][27]. As of the Oct 12, 2026 close, the stock traded around $11.93–$11.94 with an intraday market capitalization near $2.4B, and a 52-week range of $1.39–$15.88 [16][29]. Notably, the company is pre-revenue with a trailing net loss of ~$32.46M and cash of $138.34M as of June 30, 2026 [29].

Recent Catalysts (July–October 2026)